Cargando…
Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy
Introduction of new systemic therapies in the last 10 years has radically improved outcomes for melanoma patients. Even so, not all patients benefit, so getting the right treatment to the right patient is a priority. These two major drug classes, small molecule targeted kinase inhibitors and immune...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Society for Publication of Acta Dermato-Venereologica
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189745/ https://www.ncbi.nlm.nih.gov/pubmed/32346748 http://dx.doi.org/10.2340/00015555-3497 |